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Research
Perfluoroalkyl acids (PFAAs) are degradation 
products of many man-made polyfluorinated 
compounds (PFCs) used in consumer and 
industrial products, for example, for impreg-
nation of carpets, textiles, and paper (Jensen 
et al. 2008; Jensen and Leffers 2008; Kissa 
2001). Studies of environment, wildlife, and 
humans suggest widespread presence and 
exposure, persistence in the environment, and 
bioaccumulation (Giesy and Kannan 2001; 
Kannan et al. 2004). For perfluoro  octanoic 
acid (PFOA), perfluoro  octane sulfonic acid 
(PFOS), and perfluoro  hexane sulfonic acid 
(PFHxS), three of the most abundant PFAAs, 
half-lives for humans have been estimated as 
3.8, 5.4, and 8.5 years, respectively (Olsen 
et al. 2007). Some studies suggest that men 
may have higher serum concentrations 
of PFAAs than women, and younger indi-
viduals may have higher levels than older 
(Calafat et al. 2006). Thus, young men may 
have particularly high levels of exposure and 
may therefore be a group at risk for potential 
adverse effects of PFAAs.
PFAAs can cross the placental barrier 
and therefore have the potential to affect the 
fetus. In humans, levels of PFOS and PFOA 
in umbilical cord blood have been inversely 
related to birth weight (Apelberg et al. 2007). 
In addition, PFOS, PFOA, and PFHxS have 
been detected in human seminal plasma sam-
ples (Guruge et al. 2005). However, data on 
effects in humans are scarce, and most come 
from studies of occupationally exposed indi-
viduals. These studies have not given conclu-
sive evidence of adverse effects. In a recent 
study, however, Fei et al. (2009) measured 
PFAA levels in early pregnancy and found 
that higher levels of PFOS and PFOA were 
associated with significantly longer waiting 
time to pregnancy. 
Animal studies provide some evidence 
for adverse reproductive effects on animals 
exposed as adults or in utero. Exposure of 
adult male rats to PFOA reduced their testos-
terone levels and increased their estradiol lev-
els, which may partly explain earlier findings 
of induction of Leydig cell hyperplasia and/
or adenomas in the testes of exposed animals 
(Biegel et al. 1995; Cook et al. 1992).
Our objective in the present study was to 
investigate the associations between PFOS, 
PFOA, PFHxS, and other PFAAs and tes-
ticular function. Our primary hypothesis was 
that high concentrations of PFAAs would be 
associated with low testosterone levels and 
that high PFAA levels are negatively associ-
ated with semen quality variables.
Materials and Methods
Study population. Since 1996, semen qual-
ity of young men in Denmark has been sur-
veyed in a cross-sectional study (Andersen 
et al. 2000; Jørgensen et al. 2002). All young 
Danish men must report for military draft, 
and annually new cohorts of approximately 
300 men from the Copenhagen area have 
been included. They each provided one semen 
sample and had a venous blood sample drawn. 
Of the 546 men examined in 2003, we 
selected 105 for the investigation of associa-
tion between PFAAs and testicular function. 
The 105 men included the 53 men (group 1) 
with the highest testosterone levels (median, 
31.8 nmol/L; range, 30.1–34.8 nmol/L) and 
the 52 men (group 2) with the lowest testos-
terone levels (median, 14.0 nmol/L; range, 
10.5–15.5 nmol/L). We chose the men exam-
ined in 2003 because this was the latest year 
from which we had completed analyses of 
reproductive hormones. The median ages of 
men were as follows: for group 1, 18.9 years 
(range, 18.2–24.6); for group 2, 19.0 years 
(range, 18.2–25.2); and for all 105 young men, 
19.0 years (range, 18.2–25.2). Information 
on ejaculation abstinence period and hour of 
blood sampling was recorded. All samples of 
semen and blood were collected between 0830 
and 1315 hours. Serum was stored at –20°C 
until chemical analysis.
The Danish National Committee on 
Biomedical Research Ethics, Copenhagen 
Region, approved the research, and all young 
men gave written informed consent.
PFAA analysis. Thawed serum samples 
were analyzed in January 2008 for 10 different 
perfluorinated chemicals with carbon chain 
length from C6 to C13: PFHxS, perfluo-
roheptanoic acid (PFHpA), PFOA, PFOS, 
perfluoro  octane sulfonamide (PFOSA), 
perfluoro  nonanoic acid (PFNA), perfluoro-
decanoic acid (PFDA), perfluoro  undecanoic 
acid (PFUnA), perfluoro  dodecanoic acid 
(PFDoA), and perfluoro  tridecanoic acid 
(PFTrA). One milliliter of serum was spiked 
with the surrogate standards 13C8-PFOA, 
13C2-PFDA, and 13C4-PFOS and extracted 
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according to the ion pairing method described 
previously (Hansen et al. 2001). Matrix-
matched standards were prepared by spiking 
rabbit serum (Sigma Aldrich, Schnelldorf, 
Germany) with the analytes and the surrogate 
standards. Blank samples consisted of rabbit 
serum spiked with only surrogate standards. 
Standards and blanks were extracted together 
with each batch of samples.
Instrumental analysis was performed 
by liquid chromatography-tandem mass 
spectrometry (LC-MS-MS) with electro-
spray ionization. The extracts (20 µL injec-
tion volume) were chromatographed on a 
C18 Betasil column (2.1 × 50 mm; Thermo 
Hypesil-Keystone, Bellefonte, PA, USA) 
using an Agilent 1100 Series HPLC (Agilent 
Technologies, Palo Alto, CA, USA). The 
HPLC was interfaced to a triple quadrupole 
API 2000 (Sciex, Concorde, Ontario, Canada) 
equipped with a TurboIon Spray source oper-
ating in negative ion mode. Chromatographic 
conditions and transition MS-MS ions have 
been described in detail previously (Bossi et al. 
2005). The limits of detection (LODs) ranged 
from 0.1 to 0.5 ng/mL.
Reproductive hormone analysis. We ana-
lyzed thawed serum samples for the levels of 
testosterone, estradiol, sex hormone bind-
ing globulin (SHBG), luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), 
and inhibin B, as described previously (Paasch 
et al. 2008). Free androgen index (FAI) was 
calculated as (testosterone × 100/SHBG). 
Ratios between hormones were calculated by 
simple division.
Semen analysis. We assessed semen volume 
by weight and determined the sperm concen-
tration using a Bürker-Türk hemocytometer 
(Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany). We calculated total 
sperm count as semen volume × sperm con-
centration. The percentage of motile sperma-
tozoa [World Health Organization (WHO) 
class A + B + C (WHO 1999)] was assessed on 
fresh samples. Sperm morphology slides were 
fixed and Papanicolaou-stained, and all were 
assessed according to strict criteria (Menkveld 
et al. 1990) by one trained technician over 
a period of 1 week. The method for semen 
analy  sis has been described in detail previously 
(Jørgensen et al. 2002). 
Statistical analysis. We used medians and 
5–95th percentiles to describe the levels of 
PFAAs in groups 1 and 2. The Mann-Whitney 
U-test was used to compare groups 1 and 2 
with respect to PFAA levels, body mass index 
(BMI), and smoking status. Samples with val-
ues < LOD were set to 0 ng/mL. We used 
Pearson’s correlation coefficients and related 
p-values to describe correlations between levels 
of different PFCs. Univariate regression analy-
sis was performed for comparison of hormone 
levels between groups 1 and 2 and to describe 
associations between PFAAs and hormones or 
semen variables. Sperm concentration, semen 
volume, and total sperm count were adjusted 
for the effect of ejaculation abstinence period. 
Sperm motility was adjusted for time between 
ejaculation and assessment of motility. Sex hor-
mone concentrations were adjusted for hour of 
blood sampling. Semen variables and hormone 
levels and ratios, except sperm morphology 
and total testosterone, were ln-transformed 
to obtain normality of the residuals. Smoking 
and BMI were tested for confounding effects 
but, because neither was significant, we did not 
include them in the final analyses.
We analyzed for associations between 
PFAAs and testicular function (hormone levels 
and semen quality) for the whole group of 
105 men. We singled out PFOS and PFOA, 
and calculated results as estimated changes 
in end point (reproductive hormones and 
semen variables) with a change in serum con-
centration of 1 ng/mL PFOS, PFOA, or the 
summed concentration of PFOS plus PFOA. 
We divided the men into three groups from 
the combined concentrations of PFOS and 
PFOA. Each sample was given a quartile score 
of 1–4 for PFOS and PFOA levels separately. 
A score of 1 was assigned to samples with levels 
within the lowest quartile, and a score of score 
4 was assigned to those with concentrations 
within the highest quartile. We then summed 
the quartile scores for PFOS and PFOA, giving 
each sample a possible score of 2–8. Samples 
were then divided into three quartile groups 
for PFOS and PFOA combined: low-PFAA 
group (n = 29) with summed quartile score of 
2–3, intermediate-PFAA group (n = 48) with 
score of 4–6, and high-PFAA group (n = 28) 
with score of 7–8. Analysis for association 
between quartile group and hormone levels or 
semen variables was conducted using univari-
ate regression analysis, adjusted for the above-
mentioned confounders.
We performed statistical analysis using 
SPSS statistical software, version 16.0 (SPSS 
Inc., Chicago, IL, USA).
Table 2. Adjusted mean (95% CI) for PFAA quartile groups (PFOS and PFOA only). 
  Low PFAA  Intermediate PFAA  High PFAA
Parameter  (n = 29)  (n = 48)  (n = 28)  p-Value
Sex hormonesa
  Testosterone (nmol/L)  25.2 (21.7–28.7)  22.3 (19.6–25.0)  22.3 (18.8–25.8)  0.2
  Estradiol (pmol/L)  77.6 (70.3–85.8)  72.4 (67.0–84.7)  76.6 (69.3–84.7)  0.9
  SHBG (nmol/L)  27.8 (24.0–32.2)  25.4 (22.6–28.5)  26.1 (22.5–30.3)  0.5
  LH (IU/L)  3.4 (2.8–4.1)  2.9 (2.5–3.4)  3.7 (3.0–4.4)  0.6
  FSH (IU/L)  2.7 (2.1–3.5)  2.7 (2.2–3.3)  3.0 (2.3–3.8)  0.6
  Inhibin-B (pg/mL)  181 (142–232)  175 (144–212)  152 (119–195)  0.3
  FAI  84.1 (74.1–95.5)  80.2 (72.6–88.7)  77.8 (68.5–88.3)  0.4
  Testosterone/LH  6.9 (5.6–8.4)  7.0 (5.9–8.2)  5.5 (4.5–6.8)  0.1
  FAI/LH  24.7 (19.9–30.7)  27.4 (23.1–32.5)  21.2 (17.1–26.4)  0.3
  Estradiol/testosterone  3.3 (3.0–3.7)  3.6 (3.2–3.9)  3.8 (3.4–4.2)  0.1
  Inhibin/FSH  66.8 (42.1–106.0)  66.0 (45.9–94.8)  51.3 (32.3–81.4)  0.4
Semen qualityb
  Volume (mL)  4.0 (3.2–5.0)  3.4 (2.9–4.1)  3.5 (2.9–4.4)  0.3
  Concentration (million/mL)  59 (36–96)  51 (35–74)  40 (25–64)  0.2
  Total count (million)  228 (134–389)  172 (114–261)  143 (86–237)  0.1
  Motile sperm (%)  73 (69–77)  70 (66–73)  71 (66–75)  0.4
  Morphologically normal (%)  8.8 (7.2–10.4)  7.7 (6.4–9.0)  6.3 (4.6–8.0)  0.037*
  Total morphologically normal (million)  15.5 (7.3–33.0)  10.0 (5.6–17.9)  6.23 (3.0–12.8)  0.030*
CI, confidence interval. p-Values indicate differences between the high- and low-testosterone groups.
aHormone levels were adjusted for time of blood sampling. bVolume, concentration, total count, and total morphologically 
normal sperm were adjusted for duration of abstinence; motility was adjusted for time between ejaculation and semen 
analysis; and morphology was not adjusted for confounders. 
*p < 0.05.
Table 1. Median PFAA concentrations (5th–95th percentiles; ng/mL) for high- and low-testosterone groups 
and all study subjects. 
  Samples  High testosterone   Low testosterone  Whole group
PFAA  > LOD  (n = 53)  (n = 52)  (n = 105)  p-Value
PFHxS  105  6.6 (4.0–13.0)  6.6 (3.5–12.1)  6.6 (4.0–12.1)  0.8
PFHpA  98  0.2 (0.01–0.9)  0.3 (0.00–1.3)  0.2 (0.00–1.1)  0.8
PFOA  105  4.4 (2.6–7.0)  5.0 (2.7–7.5)  4.9 (2.7–7.2)  0.1
PFOS  105  25.5 (14.2– 39.6)  23.9 (12.8–45.2)  24.5 (14.2–42.1)  0.4
PFOSA  56  0.1 (0.00– 3.7)  0.00 (0.00–3.5)  0.06 (0.00–3.5)  0.008*
PFNA  105  0.8 (0.4–1.8)  0.8 (0.4–2.0)  0.8 (0.4–1.8)  0.6
PFDA  104  0.9 (0.2–1.1)  0.8 (0.4–1.2)  0.9 (0.3–1.1)  0.9
PFUnA  101  0.1 (0.04– 0.3)  0.2 (0.00–0.4)  0.1 (0.02– 0.4)  1.0
PFDoA  102  0.08 (0.04–0.8)  0.08 (0.02–0.8)  0.08 (0.04–0.8)  0.8
PFTrA  7  0.00 (0.000–0.4)  0.00 (0.00–0.06)  0.00 (0.00–0.2)  0.2
p-Values indicate differences between the high- and low-testosterone groups.
*p < 0.05.PFAAs and human semen quality
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Results
Levels of PFAAs in serum. The serum levels 
and number of samples > LOD for all PFAAs 
are shown in Table 1 for the low and high tes-
tosterone groups and for all 105 men. Except 
for PFOSA, which was detected in only 
56 men, we found no significant difference in 
levels of any PFAA between groups 1 and 2. 
The median PFOS, PFOA, and PFHxS con-
centrations for all 105 of the men were 24.5, 
4.9, and 6.6 ng/mL, respectively, and only 
these were included in the final regression 
analyses. The remaining PFAAs were found 
in much lower concentrations; therefore, 
these results are not discussed further. PFOS 
levels were positively correlated with con-
centrations of PFOA (r = 0.594, p < 0.0005) 
and PFHxS (r = 0.304, p = 0.002). PFOA 
and PFHxS levels were positively correlated 
but not statistically significantly (r = 0.136, 
p = 0.2).
PFAAs and semen variables. In the 
group of all 105 men, we found a tendency 
toward reduced levels of all semen variables 
in the high PFAA (PFOS and PFOA) quartile 
group compared with the low quartile group 
(Table 2). The difference in percentage of 
morphologically normal spermatozoa as well 
as in the total number of normal spermatozoa 
(total sperm count × percent morphologically 
normal sperm) was statistically significant 
(p = 0.037 and 0.030, respectively). In the 
high PFOS–PFOA group, the median num-
ber of normal spermatozoa in the ejaculate 
was 6.2 million compared with 15.5 million 
in the low group (Figures 1 and 2).
When associations of semen variables to 
PFOS and PFOA were analyzed separately, 
as well as the simple summed concentration 
of PFOS and PFOA, estimated changes in 
semen variables with a change in serum PFAA 
concentration of 1 ng/mL indicated negative 
but nonsignificant associations between the 
PFAAs and semen variables (Table 3).
PFAAs and reproductive hormones. We 
found no significant association between 
  testosterone levels and PFAA levels and no 
significant difference in PFAA levels between 
the high and low testosterone groups. For 
the group of 105 men, adjusted medians 
for the hormones point to a negative asso-
ciation to PFAA levels; however, none of 
these   tendencies were statistically significant 
(Table 2).
Estimated associations between reproduc-
tive hormones and PFOS and PFOA sepa-
rately, as well as the summed concentration 
of PFOS and PFOA, showed no significant 
associations (Table 4).
Smoking and BMI. Of the 105 men, 35% 
were smokers, and there were more smokers 
in the high testosterone group than in the low 
testosterone group (49% and 21% smokers, 
respectively; p = 0.003). Smoking status was 
significantly associated with higher testoster-
one, lower estradiol, and higher SHBG when 
entered as a confounder in univariate analy-
ses for these three variables only (p = 0.004–
0.009). Smoking was not associated with 
any semen quality variables (p = 0.1–0.4) or 
levels of any PFAA (p = 0.1–1.0). Including 
smoking as a confounder did not considerably 
change the presented results or significance 
levels. Therefore, we did not include smoking 
in the final analyses. BMI was not associated 
with levels of any PFAA (p = 0.1–1.0), or any 
semen variables (e.g., p = 0.5 for morpho-
logically normal sperm, and p = 0.9 for total 
number of morphologically normal sperm in 
analyses for difference between high and low 
PFAA groups).
Discussion
In this study we examined PFAA levels in 
young adult males. We found high serum 
concentrations of PFAAs to be significantly 
associated with reduced numbers of normal 
spermatozoa. In addition, sperm concentra-
tion, total sperm count, and sperm motility 
showed some tendency toward lower levels 
in men with high PFAA levels, although not 
at statistically significant levels. We also 
found a tendency toward lower inhibin B/
FSH ratio with high PFAA levels; this is espe-
cially relevant because these hormones reflect 
  spermatogenetic activity. 
Testosterone, FAI, testosterone/LH ratio, 
and testosterone/estradiol ratio could suggest a 
poorer Leydig cell function in the high-PFAA 
quartile group compared with the low-PFAA 
quartile group. However, the associations 
between reproductive hormones and PFAAs 
were not completely consistent, and none 
were significant. Therefore, this study cannot 
demon  strate an adverse effect of PFAAs on 
Leydig cell function.
Figure 1. Percent morphologically normal sperma-
tozoa by PFAA quartile group (adjusted mean and 
95% confidence interval) in all 105 men. 
*p = 0.037 compared with low PFAA quartile group. 
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Figure 2. Total morphologically normal spermato-
zoa (million) adjusted for duration of abstinence 
and PFAA quartile groups (adjusted mean and 95% 
confidence interval) in all 105 men. 
*p = 0.030 compared with low PFAA quartile group. 
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Table 3. Estimated change in semen variablesa of all 105 men with a change in PFAA of 1 ng/mL (95% CI). 
Variable  PFOS  PFOA  PFAA sumb
lnSemen volume  0.000 (–0.012 to 0.011)  –0.002 (–0.070 to 0.066)  0.000 (–0.010 to 0.010)
lnSperm concentration  –0.020 (–0.044 to 0.005)  –0.080 (–0.230 to 0.066)  –0.018 (–0.040 to 0.004)
lnTotal sperm count  –0.018 (–0.045 to 0.010)  –0.074 (–0.230 to 0.086)  –0.016 (–0.041 to 0.008)
lnSperm motility  –0.006 (–0.019 to 0.007)  –0.027 (–0.110 to 0.053)  –0.006 (–0.018 to 0.007)
Morphology  –0.085 (–0.200 to 0.026)  –0.540 (–1.200 to 0.110)  –0.082 (–0.181 to 0.018)
CI, confidence interval. 
aVolume, concentration, and total count were adjusted for duration of abstinence, motility was adjusted for time between 
ejaculation and semen analysis, and morphology was not adjusted for confounders. bSum of mass concentrations of 
PFOS and PFOA (ng/mL). 
Table 4. Estimated change in reproductive hormonesa of all 105 men with a change in PFAA concentration 
of 1 ng/mL (95% CI). 
  PFOS  PFOA  PFAA sumb
Testosterone  –0.087 (–0.32 to 0.15)  –0.98 (–2.33 to 0.37)  –0.093 (–0.303 to 0.116)
lnEstradiol  –0.001 (–0.008 to 0.005)  –0.012 (–0.051 to 0.027)  –0.001 (–0.007 to 0.005)
lnSHBG  0.002 (–0.007 to 0.012)  –0.009 (–0.067 to 0.048)  0.002 (–0.007 to 0.011)
lnLH  0.000 (–0.014 to 0.012)  –0.010 (–0.084 to 0.064)  0.000 (–0.012 to 0.010)
lnFSH  0.004 (–0.13 to 0.22)  –0.037 (–0.14 to 0.064)  0.003 (–0.013 to 0.018)
lnInhibin B  –0.004 (–0.21 to 0.12)  0.012 (–0.084 to 0.11)  –0.003 (–0.018 to 0.012)
lnFAI  –0.006 (–0.015 to 0.002)  –0.038 (–0.087 to 0.011)  –0.006 (–0.014 to 0.001)
lnTestosterone/LH  –0.003 (–0.017 to 0.011)  –0.037 (–0.12 to 0.045)  –0.003 (–0.016 to 0.009)
lnFAI/LH  –0.006 (–0.020 to 0.009)  –0.028 (–0.114 to 0.058)  –0.005 (–0.018 to 0.008)
lnEstradiol/testosterone  0.003 (–0.005 to 0.010)  0.035 (–0.010 to 0.081)  0.003 (–0.004 to 0.010)
lnInhibin/FSH  –0.009 (–0.039 to 0.022)  0.049 (–0.13 to 0.23)  –0.006 (–0.034 to 0.022)
CI, confidence interval. 
aHormone levels are adjusted for time of blood sampling. bSum of mass concentrations of PFOS and PFOA (ng/mL). Joensen et al.
926  v o l u m e  117 | n u m b e r 6 | June 2009  •  Environmental Health Perspectives
We singled out PFOS and PFOA because 
no data specifically support PFHxS as an 
endocrine disruptor, and we divided the men 
into three groups from the combined con-
centrations of PFOS and PFOA to account 
for a potential different effect at the same 
concentration levels. Because we found no 
significant association between testosterone 
levels and PFAA levels and no significant dif-
ference in PFAA levels between high and low 
testosterone groups, we analyzed associations 
between PFOS–PFOA levels and reproductive 
hormones or semen variables for the whole 
group. Controlling for confounding effect of 
smoking or BMI did not change estimates or 
significance levels. To our knowledge, there 
have been no consistent reports of associations 
between PFAA levels and smoking or BMI.
Our study included only 105 men; in 
addition, we had selected the men based 
on their serum testosterone values. The two 
groups with high and low testosterone were 
selected in order to test our primary hypoth-
esis, but this selection affects the homogeneity 
of the group when correlations are analyzed 
for the group as a whole. This could poten-
tially influence the subsequent analysis of 
semen quality by bias or confounding and 
may affect the general applicability of the 
results. A larger follow-up study would prefer-
ably include randomly selected men from the 
general population.
To our knowledge, the present study is 
the first to report a correlation between semen 
quality and PFAAs. Very few studies of other 
endocrine disruptors (e.g., phthalates, pes-
ticides) have demonstrated such an associa-
tion (Duty et al. 2003; Hauser et al. 2003, 
2007; Meeker et al. 2008; Swan et al. 2003). 
If the results from our preliminary study of 
an association between high levels of PFAAs 
and decreased number of normal sperm are 
confirmed, then high levels of PFAAs may 
be regarded as another endocrine-disrupting 
factor contributing to the low semen quality 
seen among many young men. In addition, 
the importance of mixture effects of low-dose 
exposure to multiple compounds is becom-
ing evident from animal studies but remains 
to be studied in humans (Hass et al. 2007; 
Kortenkamp et al. 2007).
The mode of action of PFAAs is not clear. 
The few animal studies that have explored 
mechanistic issues show decreased testos-
terone levels and reduced expression of ste-
roidogenesis genes associated with Leydig 
cell hyperplasia in adult animals (Biegel et al. 
1995; Shi et al. 2007), suggesting a direct 
testicular effect. Recent studies have indi-
cated that the fetal gonad is particularly sensi-
tive to exogenous factors (Skakkebæk et al. 
2001). However, our results could indicate 
that exposures later in life may contribute to 
impairment of semen quality, in line with 
other recent studies (Hauser et al. 2007). We 
speculate that morphology is perhaps more 
susceptible to this than sperm concentration 
or total sperm count. Sperm morphology has 
proven to be an important indicator of semen 
quality and fertility in a clinical setting, even 
in men with normal sperm concentration 
(Guzick et al. 2001). Interestingly, Fei et al. 
(2009) reported that higher levels of maternal 
PFOS and PFOA levels in early pregnancy 
were associated with significantly longer wait-
ing time to pregnancy. We speculate that men 
and women living together may have similar 
exposure to PFAAs and that decreased semen 
quality caused by high PFAA levels may have 
contributed to the longer waiting time to 
pregnancy in that study.
The use and emission of PFCs continue 
to increase, and PFCs are not readily cleared 
from the environment (Jensen et al. 2008; 
Prevedouros et al. 2006). Therefore, humans 
and wildlife worldwide will be exposed for 
years to come. We found positive correla-
tions between levels of different PFAAs, as 
have been reported previously (Apelberg et al. 
2007; Calafat et al. 2007; Fei et al. 2007), 
suggesting common sources of exposure. The 
PFAA levels we detected are comparable with 
those found in other countries such as Sweden 
and the Faroe Islands (Kärrman et al. 2007; 
Weihe et al. 2008), but lower than results 
from Denmark from 1996–2002 (Fei et al. 
2007). Thus, the effects we found may also 
apply to other populations. 
Conclusion
Our results indicate that higher PFAA levels 
are associated with lower numbers of normal 
sperm. In addition, we found nonsignificant 
negative associations between PFAA levels and 
other semen variables and reproductive hor-
mones. Thus, high levels of PFAAs may con-
tribute to the otherwise unexplained low semen 
quality seen in many young men. However, 
results from this preliminary study should be 
corroborated in larger studies.
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